Jefferies Group’s Intellia Therapeutics NTLA Stock Holding History

Jefferies Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$700K	Sell	12,500 -87,500	-88%	-$5.43M	0.01%	917
2022 Q2	$5.18M	Buy	100,000 +3,500	+4%	+$178K	0.04%	346
2022 Q1	$7.01M	Buy	96,500 +20,000	+26%	+$1.69M	0.04%	322
2021 Q4	$9.05M	Buy	76,500 +69,400	+977%	+$8.69M	0.05%	299
2021 Q3	$952K	Sell	7,100 -2,200	-24%	-$333K	0.01%	1012
2021 Q2	$1.51M	Buy	+9,300	New	+$724K	0.01%	849

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's NTLA Position: Q3 2022 in Review

Jefferies Group increased its Intellia Therapeutics (NTLA) stake by 7.8% in Q3 2022, buying an estimated $69.5K and bringing the position to 15,524 shares worth $869K. The position accounts for 0.01% of the portfolio, ranked #845.

Jefferies Group first reported a position in NTLA in Q4 2019 and has held it in 8 quarters since. The position peaked at $2.71M in Q1 2022. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Jefferies Group held 15,524 shares of Intellia Therapeutics worth $869K as of Q3 2022.
Jefferies Group bought 1,121 Intellia Therapeutics shares in Q3 2022, an estimated $69.5K.
Intellia Therapeutics made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #845 holding.
Jefferies Group first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 8 quarters since.
Jefferies Group's Intellia Therapeutics position peaked at $2.71M in Q1 2022.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.